Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin

Overview

Journal Am J Clin Dermatol

Specialty Dermatology

Date 2023 Jan 11

PMID 36630066

Authors

Sophia Ly

Dmitry Nedosekin

Henry K Wong

Affiliations

Soon will be listed here.

Abstract

Biologic therapies targeting B-cells are emerging as an effective strategy to treat a variety of immune-mediated diseases. One of the most studied B-cell-targeted therapies is rituximab, an anti-CD20 monoclonal antibody that exemplifies B-cell depletion therapy and has served as the prototype for other anti-CD20 monoclonal antibodies and the development of biosimilars. While there are multiple studies on the use of rituximab in dermatology, a comprehensive review of rituximab therapy in autoimmune skin conditions is lacking. In this literature review, we summarize indications, treatment efficacy, and safety of rituximab among common autoimmune diseases of the skin: pemphigus vulgaris, cutaneous lupus erythematous, dermatomyositis, systemic sclerosis, thyroid dermopathy, autoimmune pemphigoid diseases, and cutaneous vasculitis diseases. Existing data on rituximab support the approach of rituximab, biosimilars, and newer B-cell-targeting therapies in immune-mediated cutaneous diseases. Overall, rituximab, which targets CD20, provides an effective alternative or concomitant option to traditional immunosuppressants in the management of various autoimmune diseases of the skin. Further studies are necessary to expand the understanding and possible utility of B-cell-targeted therapies among autoimmune skin diseases.

Citing Articles

The consequences of SARS-CoV-2 within-host persistence.

Sigal A, Neher R, Lessells R Nat Rev Microbiol. 2024; .

PMID: 39587352 DOI: 10.1038/s41579-024-01125-y.

Associations between type 1 diabetes and autoimmune skin diseases: Mendelian randomization analysis.

Liu J, Xu Y, Liu Y, Zhu Y, Li X Heliyon. 2024; 10(12):e32781.

PMID: 38975116 PMC: 11226843. DOI: 10.1016/j.heliyon.2024.e32781.

A Comprehensive Review on the Efficacy of Anti-CD20 Therapies in Pemphigus Treatment.

Khan A, Singh A, Madke B, Bhatt D, Jangid S Cureus. 2024; 16(4):e58834.

PMID: 38784354 PMC: 11114485. DOI: 10.7759/cureus.58834.

CD20 + T lymphocytes in isolated Hashimoto's thyroiditis and type 3 autoimmune polyendocrine syndrome: a pilot study.

Stramazzo I, Mangino G, Capriello S, Romeo G, Ferrari S, Fallahi P J Endocrinol Invest. 2024; 47(11):2865-2871.

PMID: 38642306 PMC: 11473566. DOI: 10.1007/s40618-024-02370-x.

Novel Therapeutic Strategies in the Treatment of Systemic Sclerosis.

Gumkowska-Sroka O, Kotyla K, Mojs E, Palka K, Kotyla P Pharmaceuticals (Basel). 2023; 16(8).

PMID: 37630981 PMC: 10458905. DOI: 10.3390/ph16081066.

References

Bag-Ozbek A, Hui-Yuen J . Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021; 17:39-54. PMC: 7814238. DOI: 10.2147/TCRM.S252592. View

Lamberts A, Euverman H, Terra J, Jonkman M, Horvath B . Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases. Front Immunol. 2018; 9:248. PMC: 5827539. DOI: 10.3389/fimmu.2018.00248. View

Tavakolpour S, Mahmoudi H, Karami F, Elikaei Behjati S, Balighi K, Abbasi M . Investigating expression pattern of eight immune-related genes in pemphigus patients compared with the healthy controls and after rituximab therapy: Potential roles of CTLA4 and FCGR3A genes expression in outcomes of rituximab therapy. Dermatol Ther. 2020; 33(6):e14380. DOI: 10.1111/dth.14380. View

Kneisel A, Hertl M . Autoimmune bullous skin diseases. Part 2: diagnosis and therapy. J Dtsch Dermatol Ges. 2011; 9(11):927-47. DOI: 10.1111/j.1610-0387.2011.07809.x. View

Achtman J, Werth V . Pathophysiology of cutaneous lupus erythematosus. Arthritis Res Ther. 2015; 17:182. PMC: 4530484. DOI: 10.1186/s13075-015-0706-2. View

Lagerstedt M, Kotaniemi-Talonen L, Antonen J, Vaalasti A . Erosive vulvo-vaginal lichen planus treated with rituximab: A case report. Int J Gynaecol Obstet. 2021; 156(1):172-173. DOI: 10.1002/ijgo.13814. View

Rodriguez-Pla A, Vikram H, Khalid V, Wesselius L . COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review. Rheumatol Int. 2021; 41(8):1509-1514. PMC: 8180184. DOI: 10.1007/s00296-021-04905-4. View

DeWane M, Waldman R, Lu J . Dermatomyositis: Clinical features and pathogenesis. J Am Acad Dermatol. 2019; 82(2):267-281. DOI: 10.1016/j.jaad.2019.06.1309. View

Iwata H, Vorobyev A, Koga H, Recke A, Zillikens D, Prost-Squarcioni C . Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients. Orphanet J Rare Dis. 2018; 13(1):153. PMC: 6122731. DOI: 10.1186/s13023-018-0896-1. View

10.

Werth V, Joly P, Mimouni D, Maverakis E, Caux F, Lehane P . Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris. N Engl J Med. 2021; 384(24):2295-2305. DOI: 10.1056/NEJMoa2028564. View

11.

Dodds M, Hobday P, Schultz B, Maguiness S . Successful treatment of severe subacute cutaneous lupus erythematosus with rituximab in an adolescent. Pediatr Dermatol. 2018; 35(3):e189-e190. DOI: 10.1111/pde.13442. View

12.

Fenoglio R, Sciascia S, Naretto C, De Simone E, Del Vecchio G, Ferro M . Rituximab in severe immunoglobulin-A vasculitis (Henoch-Schönlein) with aggressive nephritis. Clin Exp Rheumatol. 2020; 38 Suppl 124(2):195-200. View

13.

Levine T . Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005; 52(2):601-7. DOI: 10.1002/art.20849. View

14.

Thoreau B, Chaigne B, Renaud A, Mouthon L . Pathophysiology of systemic sclerosis. Presse Med. 2021; 50(1):104087. DOI: 10.1016/j.lpm.2021.104087. View

15.

Kuye I, Smith G . The Use of Rituximab in the Management of Refractory Dermatomyositis. J Drugs Dermatol. 2017; 16(2):162-166. View

16.

Cianchini G, Masini C, Lupi F, Corona R, De Pita O, Puddu P . Severe persistent pemphigoid gestationis: long-term remission with rituximab. Br J Dermatol. 2007; 157(2):388-9. DOI: 10.1111/j.1365-2133.2007.07982.x. View

17.

Rapp M, Pentland A, Richardson C . Successful Treatment of Pemphigus Vulgaris With Ofatumumab. J Drugs Dermatol. 2018; 17(12):1338-1339. View

18.

Uthman I, Taher A, Abbas O, Menassa J, Ghosn S . Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case. Dermatology. 2008; 216(3):257-9. DOI: 10.1159/000112938. View

19.

Waldman R, DeWane M, Lu J . Dermatomyositis: Diagnosis and treatment. J Am Acad Dermatol. 2019; 82(2):283-296. DOI: 10.1016/j.jaad.2019.05.105. View

20.

Genere N, Stan M . Current and Emerging Treatment Strategies for Graves' Orbitopathy. Drugs. 2019; 79(2):109-124. DOI: 10.1007/s40265-018-1045-9. View